The CD44 Receptor Interacts with P-Glycoprotein to Promote Cell Migration and Invasion in Cancer

Invasion and metastases of cancer cells and the development of resistance to anticancer therapies are the main causes of morbidity and mortality from cancer. For more than two decades, these two important but not clearly related aspects in the biology of cancer have been extensively studied. Specifi...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 65; no. 15; pp. 6660 - 6667
Main Authors Miletti-González, Karl E., Chen, Shiling, Muthukumaran, Neelakandan, Saglimbeni, Giuseppa N., Wu, Xiaohua, Yang, Jinming, Apolito, Kevin, Shih, Weichung J., Hait, William N., Rodríguez-Rodríguez, Lorna
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Association for Cancer Research 01.08.2005
Subjects
Online AccessGet full text
ISSN0008-5472
1538-7445
DOI10.1158/0008-5472.CAN-04-3478

Cover

Abstract Invasion and metastases of cancer cells and the development of resistance to anticancer therapies are the main causes of morbidity and mortality from cancer. For more than two decades, these two important but not clearly related aspects in the biology of cancer have been extensively studied. Specifically, P-glycoprotein and CD44 have been characterized and are known to be determinants of multidrug resistance (MDR) and metastases. Despite this body of knowledge, few reports have linked the two phenotypes and only recently have there been reasons to suspect a direct connection. In this report, we show that a novel physical and genetic interaction between CD44s and P-glycoprotein is in part responsible for the correlation between MDR and invasive potential in cancer cells. P-glycoprotein–specific substrates that interfere with its function reduced in vitro invasion, migration, and the physical colocalization of CD44s and P-glycoprotein. CD44 expression in sensitive cells promoted the expression of P-glycoprotein and the MDR phenotype. RNA interference of MDR1 inhibited the rate of cell migration. These data indicate that there is a close interaction between CD44 and P-glycoprotein that results in the concurrent expression and modulation of two malignant phenotypes, invasion and MDR.
AbstractList Invasion and metastases of cancer cells and the development of resistance to anticancer therapies are the main causes of morbidity and mortality from cancer. For more than two decades, these two important but not clearly related aspects in the biology of cancer have been extensively studied. Specifically, P-glycoprotein and CD44 have been characterized and are known to be determinants of multidrug resistance (MDR) and metastases. Despite this body of knowledge, few reports have linked the two phenotypes and only recently have there been reasons to suspect a direct connection. In this report, we show that a novel physical and genetic interaction between CD44s and P-glycoprotein is in part responsible for the correlation between MDR and invasive potential in cancer cells. P-glycoprotein-specific substrates that interfere with its function reduced in vitro invasion, migration, and the physical colocalization of CD44s and P-glycoprotein. CD44 expression in sensitive cells promoted the expression of P-glycoprotein and the MDR phenotype. RNA interference of MDR1 inhibited the rate of cell migration. These data indicate that there is a close interaction between CD44 and P-glycoprotein that results in the concurrent expression and modulation of two malignant phenotypes, invasion and MDR.Invasion and metastases of cancer cells and the development of resistance to anticancer therapies are the main causes of morbidity and mortality from cancer. For more than two decades, these two important but not clearly related aspects in the biology of cancer have been extensively studied. Specifically, P-glycoprotein and CD44 have been characterized and are known to be determinants of multidrug resistance (MDR) and metastases. Despite this body of knowledge, few reports have linked the two phenotypes and only recently have there been reasons to suspect a direct connection. In this report, we show that a novel physical and genetic interaction between CD44s and P-glycoprotein is in part responsible for the correlation between MDR and invasive potential in cancer cells. P-glycoprotein-specific substrates that interfere with its function reduced in vitro invasion, migration, and the physical colocalization of CD44s and P-glycoprotein. CD44 expression in sensitive cells promoted the expression of P-glycoprotein and the MDR phenotype. RNA interference of MDR1 inhibited the rate of cell migration. These data indicate that there is a close interaction between CD44 and P-glycoprotein that results in the concurrent expression and modulation of two malignant phenotypes, invasion and MDR.
Invasion and metastases of cancer cells and the development of resistance to anticancer therapies are the main causes of morbidity and mortality from cancer. For more than two decades, these two important but not clearly related aspects in the biology of cancer have been extensively studied. Specifically, P-glycoprotein and CD44 have been characterized and are known to be determinants of multidrug resistance (MDR) and metastases. Despite this body of knowledge, few reports have linked the two phenotypes and only recently have there been reasons to suspect a direct connection. In this report, we show that a novel physical and genetic interaction between CD44s and P-glycoprotein is in part responsible for the correlation between MDR and invasive potential in cancer cells. P-glycoprotein–specific substrates that interfere with its function reduced in vitro invasion, migration, and the physical colocalization of CD44s and P-glycoprotein. CD44 expression in sensitive cells promoted the expression of P-glycoprotein and the MDR phenotype. RNA interference of MDR1 inhibited the rate of cell migration. These data indicate that there is a close interaction between CD44 and P-glycoprotein that results in the concurrent expression and modulation of two malignant phenotypes, invasion and MDR.
Author Apolito, Kevin
Shih, Weichung J.
Muthukumaran, Neelakandan
Miletti-González, Karl E.
Chen, Shiling
Saglimbeni, Giuseppa N.
Wu, Xiaohua
Yang, Jinming
Hait, William N.
Rodríguez-Rodríguez, Lorna
Author_xml – sequence: 1
  givenname: Karl E.
  surname: Miletti-González
  fullname: Miletti-González, Karl E.
– sequence: 2
  givenname: Shiling
  surname: Chen
  fullname: Chen, Shiling
– sequence: 3
  givenname: Neelakandan
  surname: Muthukumaran
  fullname: Muthukumaran, Neelakandan
– sequence: 4
  givenname: Giuseppa N.
  surname: Saglimbeni
  fullname: Saglimbeni, Giuseppa N.
– sequence: 5
  givenname: Xiaohua
  surname: Wu
  fullname: Wu, Xiaohua
– sequence: 6
  givenname: Jinming
  surname: Yang
  fullname: Yang, Jinming
– sequence: 7
  givenname: Kevin
  surname: Apolito
  fullname: Apolito, Kevin
– sequence: 8
  givenname: Weichung J.
  surname: Shih
  fullname: Shih, Weichung J.
– sequence: 9
  givenname: William N.
  surname: Hait
  fullname: Hait, William N.
– sequence: 10
  givenname: Lorna
  surname: Rodríguez-Rodríguez
  fullname: Rodríguez-Rodríguez, Lorna
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16988943$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/16061646$$D View this record in MEDLINE/PubMed
BookMark eNqFkUtP3DAURi0EKsPQnwDypuxCr-NHHHWFwlPipYqujeNxilEmHmwPaP59nTKUig3ywvqk81nX9-ygzcEPFqE9AoeEcPkdAGTBWVUeNkfXBbCCskpuoAnhVBYVY3wTTf4x22gnxsccOQH-BW0TAYIIJibo_u7B4uaYMfzTGrtIPuCLIdmgTYr4xaUHfFuc9SvjF8En6wacPL4Nfp4Dbmzf4yv3O-jk_ID1MMvdZx3HkMlGD8aGXbTV6T7ar-t7in6dntw158XlzdlFc3RZGAZlKoQGA7O6azU1kpqay1LWpOpa1lkpLJRtbaBjtAVSkjp3KtOWNbQzzkshpaRTdPD6bh70aWljUnMXTZ5QD9YvoxKSUcGAfAqSigEdzxTtr8FlO7cztQhursNKvS0vA9_WgI5G913IH3bxP66WsmY0c_yVM8HHGGz3joAaZapRlBpFqSxTAVOjzNz78aFnXPq76xS06z9p_wHctqIm
CODEN CNREA8
CitedBy_id crossref_primary_10_1016_j_apsb_2023_03_024
crossref_primary_10_1002_ijc_24573
crossref_primary_10_1007_s13277_016_5294_5
crossref_primary_10_1080_14397595_2017_1341458
crossref_primary_10_1002_ijc_23122
crossref_primary_10_1074_jbc_M800109200
crossref_primary_10_2217_fon_13_230
crossref_primary_10_1091_mbc_e10_06_0489
crossref_primary_10_1136_rmdopen_2016_000423
crossref_primary_10_3390_molecules27123714
crossref_primary_10_1007_s10330_006_0465_2
crossref_primary_10_1016_j_critrevonc_2018_09_017
crossref_primary_10_1038_sj_bjc_6605839
crossref_primary_10_3109_1061186X_2012_702767
crossref_primary_10_1021_acs_molpharmaceut_9b00189
crossref_primary_10_1080_2162402X_2015_1108513
crossref_primary_10_1158_0008_5472_CAN_08_2491
crossref_primary_10_1158_1078_0432_CCR_13_1536
crossref_primary_10_1111_jebm_12434
crossref_primary_10_1002_pmic_201800165
crossref_primary_10_1007_s12262_012_0616_3
crossref_primary_10_1248_yakushi_22_00108
crossref_primary_10_18632_oncotarget_4763
crossref_primary_10_1007_s00280_008_0684_z
crossref_primary_10_1016_j_jbc_2024_107299
crossref_primary_10_1016_j_apsb_2024_01_007
crossref_primary_10_1021_nn501223q
crossref_primary_10_1177_0271678X16671147
crossref_primary_10_1016_j_apsusc_2015_01_204
crossref_primary_10_3109_10428194_2011_572323
crossref_primary_10_3389_fonc_2020_589601
crossref_primary_10_1186_1471_2407_13_476
crossref_primary_10_18632_oncotarget_5290
crossref_primary_10_18632_oncotarget_15879
crossref_primary_10_1002_mc_22376
crossref_primary_10_1016_j_ajpath_2024_12_004
crossref_primary_10_1002_mc_22021
crossref_primary_10_1016_j_bbrc_2008_05_012
crossref_primary_10_1016_j_jddst_2019_01_042
crossref_primary_10_1016_j_tranon_2024_102168
crossref_primary_10_1007_s10330_006_0477_y
crossref_primary_10_1254_jphs_09323FP
crossref_primary_10_3389_fimmu_2015_00201
crossref_primary_10_1007_s11033_019_05058_1
crossref_primary_10_1007_s11523_012_0247_4
crossref_primary_10_1158_1541_7786_MCR_15_0466
crossref_primary_10_12677_WJCR_2023_134022
crossref_primary_10_1016_j_canlet_2015_03_034
crossref_primary_10_1016_j_bcp_2013_11_003
crossref_primary_10_1177_2058739219845155
crossref_primary_10_1016_j_semcancer_2008_03_009
crossref_primary_10_1021_acs_bioconjchem_5b00551
crossref_primary_10_1016_j_taap_2022_115887
crossref_primary_10_3389_fonc_2014_00220
crossref_primary_10_1016_j_yexcr_2006_08_030
crossref_primary_10_2147_OTT_S286639
crossref_primary_10_3390_cancers16244187
crossref_primary_10_1007_s11060_016_2058_4
crossref_primary_10_1158_1541_7786_MCR_05_0232
crossref_primary_10_1016_j_semcdb_2015_03_009
crossref_primary_10_1371_journal_pgen_1001383
crossref_primary_10_1136_ijgc_2021_003316
crossref_primary_10_1038_srep11365
crossref_primary_10_1002_smll_202003309
crossref_primary_10_1016_j_biocel_2018_07_003
crossref_primary_10_3390_cancers13225644
crossref_primary_10_3892_or_2012_1951
crossref_primary_10_3389_fcell_2023_1124960
crossref_primary_10_1111_jgh_13069
crossref_primary_10_1007_s10529_010_0423_5
crossref_primary_10_1007_s00441_009_0780_3
crossref_primary_10_3892_ijo_2015_3299
crossref_primary_10_1074_jbc_M111_318774
crossref_primary_10_3892_ol_2013_1321
crossref_primary_10_1016_j_yexmp_2014_12_001
crossref_primary_10_1111_jcmm_13810
crossref_primary_10_1111_ijlh_13455
crossref_primary_10_1038_srep08509
crossref_primary_10_3390_molecules21030290
crossref_primary_10_1080_1040841X_2019_1607248
crossref_primary_10_1158_1078_0432_CCR_09_0479
crossref_primary_10_2174_1568009620666200506110850
crossref_primary_10_1038_s12276_017_0008_7
crossref_primary_10_1002_ar_24147
crossref_primary_10_1158_1078_0432_CCR_06_1307
crossref_primary_10_1002_jcb_28948
crossref_primary_10_1016_j_ygyno_2019_10_021
crossref_primary_10_1038_nrc2789
crossref_primary_10_3390_ijms22063199
crossref_primary_10_1038_sj_jid_5701082
crossref_primary_10_3892_ijmm_2018_3381
crossref_primary_10_1016_j_matbio_2018_04_012
crossref_primary_10_1038_sj_bjc_6605185
crossref_primary_10_1002_iub_2669
crossref_primary_10_1007_s10549_011_1692_y
crossref_primary_10_1002_gcc_20492
crossref_primary_10_1016_j_bbadis_2024_167549
crossref_primary_10_1038_s41598_019_46700_z
crossref_primary_10_1158_1078_0432_CCR_14_2141
crossref_primary_10_1016_j_bbcan_2010_06_004
crossref_primary_10_1016_j_biomaterials_2014_12_030
crossref_primary_10_1155_2012_504918
crossref_primary_10_1007_s13277_015_4755_6
crossref_primary_10_1016_j_leukres_2010_02_020
crossref_primary_10_3390_ijms17101718
crossref_primary_10_4103_ijpvm_IJPVM_135_20
crossref_primary_10_1042_BST20150137
crossref_primary_10_1186_bcr2111
crossref_primary_10_1074_jbc_M109_027466
crossref_primary_10_3389_fcell_2018_00097
crossref_primary_10_1186_scrt13
crossref_primary_10_1080_1061186X_2017_1289538
crossref_primary_10_3390_ijms241310627
crossref_primary_10_1038_nrc3023
crossref_primary_10_1186_1471_2407_11_290
crossref_primary_10_1002_1878_0261_13551
crossref_primary_10_3390_jcm7100330
crossref_primary_10_1016_j_gde_2005_12_008
crossref_primary_10_1016_j_canlet_2008_12_015
crossref_primary_10_1038_sj_onc_1209724
crossref_primary_10_1007_s00432_015_2029_8
crossref_primary_10_1007_s10047_012_0644_6
crossref_primary_10_1158_1078_0432_CCR_09_2317
crossref_primary_10_1016_j_pharmthera_2008_04_008
crossref_primary_10_1021_mp500435s
crossref_primary_10_4137_CGM_S3716
crossref_primary_10_1245_s10434_009_0395_7
crossref_primary_10_1158_0008_5472_CAN_09_0143
crossref_primary_10_1093_noajnl_vdab030
crossref_primary_10_3390_ijms161024772
crossref_primary_10_3390_cells8101150
crossref_primary_10_1016_j_drup_2008_04_002
crossref_primary_10_1007_s12015_016_9660_x
crossref_primary_10_1111_j_1751_553X_2009_01149_x
crossref_primary_10_1093_annonc_mdl074
crossref_primary_10_1016_j_heliyon_2022_e11171
crossref_primary_10_1371_journal_pone_0000243
crossref_primary_10_1038_sj_emboj_7601039
crossref_primary_10_3390_biomedicines10020414
crossref_primary_10_1111_j_1447_0756_2006_00422_x
crossref_primary_10_3390_ijms24087331
crossref_primary_10_1016_j_heliyon_2022_e09777
crossref_primary_10_3402_jev_v3_24384
crossref_primary_10_2217_epi_2016_0030
crossref_primary_10_1177_0271678X18767748
crossref_primary_10_1016_j_ajpath_2013_01_019
crossref_primary_10_1007_s13277_011_0155_8
crossref_primary_10_3390_ijms23158616
crossref_primary_10_1002_hep_22704
crossref_primary_10_1134_S0006297918070015
crossref_primary_10_1080_10408398_2018_1551778
Cites_doi 10.1007/BF00692343
10.1002/path.1400
10.1073/pnas.89.24.12160
10.1002/ijc.2910430121
10.1016/0092-8674(90)90694-A
10.1002/jcp.1041630314
10.1007/BF00665804
10.1016/S0065-230X(08)60101-3
10.1101/gad.13.1.35
10.1080/0031302031000150524
10.1016/S0959-8049(01)00086-7
10.1074/jbc.C300173200
10.1158/1078-0432.CCR-03-0517
10.1016/S0006-291X(86)80136-X
10.1124/mol.66.2.268
10.1158/1078-0432.CCR-03-0610
10.1172/JCI200316200
10.1016/S0014-5793(00)01087-5
10.1200/JCO.1990.8.4.689
10.1111/j.1349-7006.2001.tb01162.x
10.1007/s002800050449
10.1038/sj.onc.1206948
10.1016/S0006-2952(97)82451-3
10.1093/jnci/83.2.111
10.1074/jbc.273.1.338
10.1158/0008-5472.CAN-03-2832
ContentType Journal Article
Copyright 2005 INIST-CNRS
Copyright_xml – notice: 2005 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7TO
H94
7X8
DOI 10.1158/0008-5472.CAN-04-3478
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Oncogenes and Growth Factors Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Oncogenes and Growth Factors Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef
MEDLINE
Oncogenes and Growth Factors Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1538-7445
EndPage 6667
ExternalDocumentID 16061646
16988943
10_1158_0008_5472_CAN_04_3478
Genre Research Support, U.S. Gov't, P.H.S
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: CA 72720
– fundername: NCI NIH HHS
  grantid: CA 66077
GroupedDBID ---
-ET
.55
.GJ
18M
29B
2WC
34G
39C
3O-
53G
5GY
5RE
5VS
6J9
8WZ
A6W
AAFWJ
AAJMC
AAYXX
ABOCM
ACGFO
ACIWK
ACPRK
ACSVP
ADBBV
ADCOW
AENEX
AETEA
AFFNX
AFHIN
AFOSN
AFRAH
AFUMD
AI.
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
C1A
CITATION
CS3
DIK
DU5
EBS
EJD
F5P
FRP
GX1
H13
IH2
KQ8
L7B
LSO
MVM
OHT
OK1
P0W
P2P
PQQKQ
RCR
RHI
RNS
SJN
TR2
UDS
VH1
W2D
W8F
WH7
WHG
WOQ
X7M
XJT
YKV
YZZ
ZCG
ZGI
ADNWM
D0S
IQODW
J5H
CGR
CUY
CVF
ECM
EIF
NPM
RHF
VXZ
7TO
H94
7X8
ID FETCH-LOGICAL-c402t-6a0c0d9fba3c83c95828917fb4fe86e02b9c0f43b01219c407cb290bd55268883
ISSN 0008-5472
IngestDate Fri Sep 05 04:23:18 EDT 2025
Thu Sep 04 18:58:45 EDT 2025
Wed Feb 19 01:53:58 EST 2025
Mon Jul 21 09:12:23 EDT 2025
Tue Jul 01 01:17:41 EDT 2025
Thu Apr 24 23:10:56 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 15
Keywords Antineoplastic agent
Cell motility
Phenotype
Multiple resistance
P Glycoprotein
Metastasis
Malignant tumor
Invasion
Cell migration
Biological receptor
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c402t-6a0c0d9fba3c83c95828917fb4fe86e02b9c0f43b01219c407cb290bd55268883
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 16061646
PQID 17403030
PQPubID 23462
PageCount 8
ParticipantIDs proquest_miscellaneous_68436401
proquest_miscellaneous_17403030
pubmed_primary_16061646
pascalfrancis_primary_16988943
crossref_primary_10_1158_0008_5472_CAN_04_3478
crossref_citationtrail_10_1158_0008_5472_CAN_04_3478
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2005-08-01
PublicationDateYYYYMMDD 2005-08-01
PublicationDate_xml – month: 08
  year: 2005
  text: 2005-08-01
  day: 01
PublicationDecade 2000
PublicationPlace Philadelphia, PA
PublicationPlace_xml – name: Philadelphia, PA
– name: United States
PublicationTitle Cancer research (Chicago, Ill.)
PublicationTitleAlternate Cancer Res
PublicationYear 2005
Publisher American Association for Cancer Research
Publisher_xml – name: American Association for Cancer Research
References 2023011120191192500_B30
2023011120191192500_B31
2023011120191192500_B10
2023011120191192500_B32
2023011120191192500_B11
2023011120191192500_B33
2023011120191192500_B12
2023011120191192500_B34
2023011120191192500_B13
2023011120191192500_B35
2023011120191192500_B14
2023011120191192500_B36
2023011120191192500_B15
2023011120191192500_B37
2023011120191192500_B16
2023011120191192500_B38
2023011120191192500_B17
2023011120191192500_B39
2023011120191192500_B29
2023011120191192500_B1
2023011120191192500_B2
2023011120191192500_B3
2023011120191192500_B4
2023011120191192500_B5
2023011120191192500_B6
2023011120191192500_B7
2023011120191192500_B8
2023011120191192500_B9
2023011120191192500_B20
2023011120191192500_B21
2023011120191192500_B22
2023011120191192500_B23
2023011120191192500_B24
2023011120191192500_B25
2023011120191192500_B26
2023011120191192500_B27
2023011120191192500_B28
2023011120191192500_B18
2023011120191192500_B19
References_xml – ident: 2023011120191192500_B17
  doi: 10.1007/BF00692343
– ident: 2023011120191192500_B26
– ident: 2023011120191192500_B39
  doi: 10.1002/path.1400
– ident: 2023011120191192500_B9
  doi: 10.1073/pnas.89.24.12160
– ident: 2023011120191192500_B35
  doi: 10.1002/ijc.2910430121
– ident: 2023011120191192500_B6
  doi: 10.1016/0092-8674(90)90694-A
– ident: 2023011120191192500_B31
  doi: 10.1002/jcp.1041630314
– ident: 2023011120191192500_B12
  doi: 10.1007/BF00665804
– ident: 2023011120191192500_B2
– ident: 2023011120191192500_B7
  doi: 10.1016/S0065-230X(08)60101-3
– ident: 2023011120191192500_B37
– ident: 2023011120191192500_B14
– ident: 2023011120191192500_B32
  doi: 10.1101/gad.13.1.35
– ident: 2023011120191192500_B15
  doi: 10.1080/0031302031000150524
– ident: 2023011120191192500_B16
– ident: 2023011120191192500_B38
  doi: 10.1016/S0959-8049(01)00086-7
– ident: 2023011120191192500_B5
  doi: 10.1074/jbc.C300173200
– ident: 2023011120191192500_B28
  doi: 10.1158/1078-0432.CCR-03-0517
– ident: 2023011120191192500_B23
– ident: 2023011120191192500_B25
– ident: 2023011120191192500_B21
– ident: 2023011120191192500_B18
  doi: 10.1016/S0006-291X(86)80136-X
– ident: 2023011120191192500_B22
  doi: 10.1124/mol.66.2.268
– ident: 2023011120191192500_B3
  doi: 10.1158/1078-0432.CCR-03-0610
– ident: 2023011120191192500_B33
  doi: 10.1172/JCI200316200
– ident: 2023011120191192500_B19
  doi: 10.1016/S0014-5793(00)01087-5
– ident: 2023011120191192500_B27
– ident: 2023011120191192500_B1
– ident: 2023011120191192500_B11
  doi: 10.1200/JCO.1990.8.4.689
– ident: 2023011120191192500_B29
  doi: 10.1111/j.1349-7006.2001.tb01162.x
– ident: 2023011120191192500_B36
– ident: 2023011120191192500_B24
  doi: 10.1007/s002800050449
– ident: 2023011120191192500_B10
  doi: 10.1038/sj.onc.1206948
– ident: 2023011120191192500_B20
  doi: 10.1016/S0006-2952(97)82451-3
– ident: 2023011120191192500_B34
– ident: 2023011120191192500_B13
  doi: 10.1093/jnci/83.2.111
– ident: 2023011120191192500_B30
– ident: 2023011120191192500_B8
  doi: 10.1074/jbc.273.1.338
– ident: 2023011120191192500_B4
  doi: 10.1158/0008-5472.CAN-03-2832
SSID ssj0005105
Score 2.292404
Snippet Invasion and metastases of cancer cells and the development of resistance to anticancer therapies are the main causes of morbidity and mortality from cancer....
SourceID proquest
pubmed
pascalfrancis
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 6660
SubjectTerms ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors
ATP-Binding Cassette, Sub-Family B, Member 1 - biosynthesis
ATP-Binding Cassette, Sub-Family B, Member 1 - genetics
ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism
Biological and medical sciences
Cell Line, Tumor
Cell Membrane - metabolism
Cell Movement - drug effects
Cell Movement - physiology
Dissemination
Drug Resistance, Neoplasm
Female
Flupenthixol - pharmacology
Humans
Hyaluronan Receptors - biosynthesis
Hyaluronan Receptors - genetics
Hyaluronan Receptors - metabolism
Immunoprecipitation
Medical sciences
Neoplasm Invasiveness
Neoplasms - drug therapy
Neoplasms - metabolism
Neoplasms - pathology
RNA Interference
Transfection
Tumor cell
Tumors
Title The CD44 Receptor Interacts with P-Glycoprotein to Promote Cell Migration and Invasion in Cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/16061646
https://www.proquest.com/docview/17403030
https://www.proquest.com/docview/68436401
Volume 65
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBASmriODhh-4K1KycVJnMep7CJYC2it1LfguHZXLWuqNkViT_x0ji9JU6nTgJcosmJH8vfl5PhcEfoQ0DjxeRI4YRRnDhEed5gUnsM8LpMJ49LXzWD6g-h8RD6Pw3Gr9bsRtbQusy6_3ZlX8j-owhjgqrJk_wHZelEYgHvAF66AMFz_GuPeJ0I6ILbEotSh5SqjmFdJa9-caf6LF7oYgwpoLFQ8FoAjOspg37mZTS0BTA2mn2xlQx-5IsOyqbn29EjHFge60t5fE8ahxUyedxtGhT7ImrKcOWfF_Fa74r3cWKq_sGXeTH4wQu9SWXXsL1SDX16tr1Xst7HODoTI2bUyedRMvmTTfHaTCd2QqnM2W6_EYsGsX6kyYoR1CN1GMFMnJPGWYDZNJCoChg0xC2cud7f8D6kJmDSrdXvHA-36IaZP0Ha97cHX9HR0cZEOT8bDB-ihH4P2pdz63zf15kMbBFstaHPA4DUfd75kS7t5smAr-NCk6ZBy9xFGqzLDp2jfnkHwsSHUM9QS8-foUd9GWbxAP4BXWPEKV7zCNa-w4hXe5hUuC2x5hRWvcM0rDKDhildwgw2vXqLR6cmwd-7YThwOJ65fOhFzuTtJZMYCTgOeKF8rnPNlRqSgkXD9LOGuJEGmKgQmMCfmmZ-42SRU1YQoDV6hvXkxF68RljTkHkiBMJ54hBFJozjwXRKJREoqWNJGpNrBlNsy9apbSp7q42pIVbgETdXGp7DxqUtStfFt1K2nLUydlvsmHG3Bs5kVJVQ1JWij9xVeKYhctX1sLor1KoVDPPwaA_fuJyJKgoi4XhsdGKAbq4MCHZHo8N65b9DjzZfyFu2Vy7V4BwpwmR1pjv4B93Otog
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+CD44+receptor+interacts+with+P-glycoprotein+to+promote+cell+migration+and+invasion+in+cancer&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Miletti-Gonz%C3%A1lez%2C+Karl+E&rft.au=Chen%2C+Shiling&rft.au=Muthukumaran%2C+Neelakandan&rft.au=Saglimbeni%2C+Giuseppa+N&rft.date=2005-08-01&rft.issn=0008-5472&rft.volume=65&rft.issue=15&rft.spage=6660&rft_id=info:doi/10.1158%2F0008-5472.CAN-04-3478&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon